TrialClinical pharmacokinetics2018

A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A.

Koichiro Yoneyama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.